Skip to content
Clinical Trials – home

Fachaerztliche Gemeinschaftspraxis fuer Dermatologie Und Venerologie Allergologie Umweltmedizin Lasermedizin GbR

Research site

Germany Am Bahnhof 1, Mahlow, 15831 Blankenfelde-Mahlow, Germany

  • 7 trials recruiting
  • Dermatitis atopic · Psoriasis · Hidradenitis
  • Adults and children

About Specializations

Fachaerztliche Gemeinschaftspraxis fuer Dermatologie Und Venerologie Allergologie Umweltmedizin Lasermedizin GbR in Blankenfelde-Mahlow, Germany specialises in clinical trials of conditions such as Dermatitis atopic, Psoriasis, Hidradenitis, Hand dermatitis, and other specialisations. This site conducts important research.

Main research areas of the site

Immune-Mediated Skin Disease Research

At this dermatology and allergology site in Blankenfelde-Mahlow, much of the clinical trial activity focuses on immune system diseases and skin and connective tissue diseases. The studies mainly involve atopic dermatitis, psoriasis, and hidradenitis suppurativa, with the aim of testing new treatment options and understanding how well emerging therapies control long-term disease.

  • Atopic dermatitis research exploring new ways to improve symptom control and durability of response
  • Psoriasis studies assessing treatment effectiveness and safety in moderate to severe disease
  • Hidradenitis suppurativa trials evaluating whether newer therapies can reduce inflammation and disease activity

The site’s work is centered on finding better options for chronic inflammatory skin conditions that can affect daily comfort, appearance, and quality of life.

Atopic Dermatitis and Eczema Studies

A large share of the research at the Fachaerztliche Gemeinschaftspraxis fuer Dermatologie Und Venerologie Allergologie Umweltmedizin Lasermedizin GbR is dedicated to atopic dermatitis and related eczema conditions, including nummular dermatitis. These trials are designed to evaluate new therapies, compare them with placebo or existing care, and examine whether they can offer sustained benefit for people with moderate to severe disease.

  • Atopic dermatitis treatment studies focused on improving long-term disease control
  • Nummular dermatitis research aimed at better symptom relief and effectiveness
  • Trials assessing whether newer medicines can help patients who have not responded well to prior treatment

This area reflects a strong interest in advancing care for persistent inflammatory skin disease through better symptom management and safer, more effective options.

Psoriasis and Psoriatic Disease Trials

Another major focus is psoriasis, especially plaque psoriasis, psoriasis vulgaris, and moderate to severe plaque type psoriasis. The research aims to compare novel therapies, confirm treatment effectiveness, and evaluate longer-term safety for people living with chronic inflammatory skin disease, including those with psoriatic arthritis.

  • Plaque psoriasis studies testing new treatment approaches for better skin clearance
  • Psoriatic arthritis research addressing skin and joint-related disease burden
  • Long-term evaluations of treatment safety, tolerability, and sustained benefit

These trials support the search for more durable and convenient therapies for patients with ongoing psoriasis-related symptoms.

Hidradenitis Suppurativa and Inflammatory Lesion Research

The site also contributes to clinical research in hidradenitis suppurativa, including moderate to severe hidradenitis suppurativa. These studies are focused on testing whether newer therapies can reduce disease activity, improve response rates, and support long-term management of this painful and often difficult-to-treat condition.

  • Hidradenitis suppurativa trials evaluating new options for inflammatory skin lesions
  • Research aimed at improving response in moderate to severe disease
  • Studies examining safety and sustained effectiveness over time

This field is especially important for patients seeking better control of recurring flare-ups and chronic discomfort.

Vitiligo and Pigment Disorder Studies

Clinical trials at the site also include vitiligo, particularly non-segmental vitiligo. The purpose of this research is to assess whether new treatments can help restore skin pigmentation and improve outcomes for people with visible pigment loss.

  • Non-segmental vitiligo studies focused on treatment effectiveness
  • Research aimed at improving repigmentation and disease control
  • Comparisons of investigational therapies with placebo to understand added benefit

These studies address both medical need and the visible impact of pigment disorders on daily life and self-confidence.

Physical Phenomena and Aesthetic Dermatology Research

In addition to inflammatory skin disease, the site participates in research under physical phenomena and aesthetic dermatology topics, including treatment of upper facial lines and platysma prominence. These trials are intended to evaluate whether new approaches can improve appearance and patient satisfaction in facial and neck-related concerns.

  • Upper facial lines studies assessing visible improvement and patient-reported results
  • Platysma prominence research focused on cosmetic and functional appearance outcomes
  • Trials designed to test safety, tolerability, and aesthetic effectiveness

This area broadens the site’s portfolio beyond chronic inflammatory disease into appearance-related dermatologic care.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Am Bahnhof 1, Mahlow15831 Blankenfelde-MahlowGermany
Recruiting now
7 trials
Conditions studied
12

More sites in Blankenfelde-MahlowGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

39 clinical trials

Eczema nummular

Recruiting

A study to evaluate the effectiveness and safety of lebrikizumab in adults with nummular eczema who do not respond well to topical corticosteroids.

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Almirall S.A.

Psoriasis

Recruiting

Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study Testing How Well Bimekizumab Works and How Safe It Is for Adults with Palmoplantar Pustulosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Long-term safety and effectiveness study of APG777 injection in patients with moderate-to-severe atopic dermatitis who previously received APG777 treatment

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:APG777
  • Sponsor:Apogee Therapeutics Inc.

Hidradenitis

Recruiting

A safety and efficacy study of SAR445399 in adults with moderate to severe hidradenitis suppurativa

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SAR445399
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Hidradenitis

Recruiting

A Study of LAD191 Compared to Placebo and Adalimumab in Adults with Moderate-to-Severe Hidradenitis Suppurativa

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Adalimumab
  • Sponsor:Almirall S.A.

Skin wrinkling

Recruiting

Study on the Safety and Effectiveness of IPN10200 and Botulinum Toxin Type A for Adults with Moderate to Severe Upper Facial Lines

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A - Haemagglutinin Complex
  • Sponsor:Ipsen Innovation

Acne

Not yet recruiting

Safety and Efficacy Study of the Acne mRNA vaccine (mrt1800, mrt1801, mrt1802) in Adults 18‑45 Years with Moderate to Severe Acne

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Sponsor:Sanofi Vaccines US Inc.

Psoriasis

Not yet recruiting

Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Janssen Cilag International

Dermatitis atopic

Not recruiting

A study to evaluate the safety and effectiveness of galvokimig in adults with moderate to severe atopic dermatitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:UCB Biopharma

Psoriasis

Not recruiting

Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.